1. Home
  2. PYPD vs NEPH Comparison

PYPD vs NEPH Comparison

Compare PYPD & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PYPD
  • NEPH
  • Stock Information
  • Founded
  • PYPD 2008
  • NEPH 1997
  • Country
  • PYPD Israel
  • NEPH United States
  • Employees
  • PYPD N/A
  • NEPH N/A
  • Industry
  • PYPD Medical/Dental Instruments
  • NEPH Medical/Dental Instruments
  • Sector
  • PYPD Health Care
  • NEPH Health Care
  • Exchange
  • PYPD Nasdaq
  • NEPH Nasdaq
  • Market Cap
  • PYPD 35.3M
  • NEPH 36.1M
  • IPO Year
  • PYPD 2020
  • NEPH 2004
  • Fundamental
  • Price
  • PYPD $3.51
  • NEPH $4.00
  • Analyst Decision
  • PYPD Strong Buy
  • NEPH Buy
  • Analyst Count
  • PYPD 5
  • NEPH 1
  • Target Price
  • PYPD $11.40
  • NEPH $5.00
  • AVG Volume (30 Days)
  • PYPD 1.4M
  • NEPH 66.3K
  • Earning Date
  • PYPD 08-13-2025
  • NEPH 08-07-2025
  • Dividend Yield
  • PYPD N/A
  • NEPH N/A
  • EPS Growth
  • PYPD N/A
  • NEPH N/A
  • EPS
  • PYPD N/A
  • NEPH 0.08
  • Revenue
  • PYPD N/A
  • NEPH $15,517,000.00
  • Revenue This Year
  • PYPD N/A
  • NEPH $17.06
  • Revenue Next Year
  • PYPD N/A
  • NEPH $12.20
  • P/E Ratio
  • PYPD N/A
  • NEPH $54.66
  • Revenue Growth
  • PYPD N/A
  • NEPH 10.34
  • 52 Week Low
  • PYPD $2.30
  • NEPH $1.36
  • 52 Week High
  • PYPD $4.49
  • NEPH $5.00
  • Technical
  • Relative Strength Index (RSI)
  • PYPD 56.85
  • NEPH 58.16
  • Support Level
  • PYPD $3.45
  • NEPH $3.77
  • Resistance Level
  • PYPD $3.62
  • NEPH $4.39
  • Average True Range (ATR)
  • PYPD 0.20
  • NEPH 0.48
  • MACD
  • PYPD -0.01
  • NEPH -0.05
  • Stochastic Oscillator
  • PYPD 63.57
  • NEPH 48.50

About PYPD PolyPid Ltd.

PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.

About NEPH Nephros Inc.

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.

Share on Social Networks: